Navigation Links
Panel suggests selling allergy drugs OTC

An advisory committee to the U.S. Food and Drug Administration recommended that three popular allergy drugs are safe enough to be used without a prescription. The FDA does not have to follow the advice of its advisory committee, though it usually does. There is no deadline for making a decision. //

"Drugs are prescription for a reason. They have the ability to do both good and harm. Claritin, Allegra and Zyrtec have almost no side effects and are equally effective as the antihistamines that are available over the counter today." said Robert Seidman, WellPoint's chief pharmacy officer.

Anti-allergy medications have been linked to side effects in some users that include reduced alertness, nausea and headache. By prescription, the drugs cost about $80 per month versus $10 to $15 in the 17 nations where the drugs are over-the-counter. The drug makers oppose a switch, which would cost them money.

Usually, drug companies support making a drug over-the-counter only when their patent is about to run out, because doing so at that time extends the period during which makers of generic drugs are prohibited from selling lower-priced versions of the drug.

Claritin's patent is due to expire in 2002, but the company is waging a multi-million-dollar campaign to get it extended. Aventis Pharmaceuticals, which manufactures Allegra, also expressed its disappointment. According to WellPoint, sales of Allegra, Claritin and Zyrtec exceeded $5 billion last year.
'"/>




Page: 1

Related medicine news :

1. Anti-Quota Stir: Resident Docs Demand Experts Panel
2. Circumcision Studies to Continue Says Health Panel
3. Panel to Help Combat HIV/AIDS In Asia-Pacific Region
4. Breast Cancer Review Panel Adds Two Experts
5. Shingles Vaccine For Older People - Panel Recommendation
6. Complaints Against US Federal lab Over-ruled by Panel
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Generic Biologics – U.S Panel Hearing Draws Mixed Response
9. Expert Panel Sets Limits on Pesticide Residues in Soft Drinks
10. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
11. National Pharmaceutical Policy Referred to Ministerial Panel
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled ... wearable activity and sleep monitoring solutions for the global scientific community. The company’s ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: